Pancreatic beta-cell failure in the pathogenesis of type 2 diabetes by Gunton, Jenny & Girgis, Christian M.
5Pancreatic beta-cell failure in the pathogenesis  
of type 2 diabetes
Jenny Gunton1,2 and Christian M Girgis1,2
As the worldwide prevalence of type 2 diabetes continues to rise, there is mounting 
evidence that failure of the cells which make insulin – termed pancreatic beta (or β) cells, 
play a fundamental role at all stages in the pathogenesis. Beta-cell defects such as loss of the 
initial (first) phase of insulin secretion and inefficient insulin synthesis are seen years prior 
to the onset of type 2 diabetes. Later, it is the failure of beta cells to adequately respond to 
the demand for high insulin requirements that determines the onset of hyperglycaemia 
leading to the clinical diagnosis of type 2 diabetes. In this chapter, we will discuss the 
various proposed mechanisms of beta-cell failure in type 2 diabetes and address recent 
controversies in this field of research.
The prevalence of type 2 diabetes is rising at an alarming rate. In Australia alone, those 
affected by type 2 diabetes doubled from 3.4% in 1981 to 7.4% in a national sample of 
11 247 adults in 1999 to 2002. An additional 16.4% of participants showed symptoms of 
prediabetes in this study, a sign of imminent trouble. 
On a global scale, the International Diabetes Foundation projected that by 2030, up to 
438 million people may be affected by this disease, accounting for more than 4.5% of the 
world’s projected population [3]. China, the world’s most populous nation, has not been 
spared as a recent survey reported a remarkably high diabetes prevalence of 9.7% (92.4 
million adults) [4]. 
The burden of diabetes spans beyond the threat it poses to the individual sufferer and 
includes the greater effect on communities, the health economy and workforce. The 
estimated financial cost of type 2 diabetes in Australia is A$10.3 billion per annum which 
includes costs for carers (>A$4 billion), productivity losses (A$4.1 billion), direct costs to 
the healthcare system and the estimated direct costs of obesity (A$2.2 billion) [5].
Modern life is largely to blame for this surge in diabetes prevalence with the abundance 
of calorie-rich foods, the gross reduction in energy expenditure resulting from the use 
1  Diabetes and Transcription Factors Group, Garvan Institute of Medical Research, Sydney.
2  Sydney Medical School, University of Sydney.
88 • A modern epidemic
of cars and other labour-saving devices, the hours spent sitting in front of television or 
computer screens and the avoidance of outdoor activities. As described in earlier chapters, 
it is the collusion of such environmental factors with an individual’s genetic predisposition 
that lead to pancreatic beta-cell failure that is characteristic of type 2 diabetes. However, 
the precise pathologic processes by which beta cells fail in their essential role in glucose 
homeostasis are incompletely understood and contentious.
This chapter will outline some of the proposed mechanisms of beta-cell failure in type 2 
diabetes and touch on a couple of controversial issues that have characterised this field of 
research. However, it will first lay the groundwork with some basic principles in beta-cell 
physiology.
The beta cell 
Since the initial description of the pancreatic islet by Paul Langerhans in 1869 as ‘a network 
of small cells, almost perfect in homogeneity and structure, arranged in groups, scattered 
amongst the acinar cells of the pancreas’ [6], understanding of this highly complex mini-
organ has increased greatly. Five different endocrine cell types are found within the 
pancreatic islet, namely alpha cells that make glucagon, beta cells that make insulin, delta 
cells that make somatostatin, PP cells that make pancreatic polypeptide and epsilon cells 
that make ghrelin [7]. 
Although islets cells account for only 1%–2% of the pancreatic mass [8, 9], they receive 
10% of the total pancreatic blood flow and are surrounded by a highly specialised system 
of fenestrated endothelial cells which provide critical signals for cell differentiation, 
development and function [10]. Other extracellular components, including extracellular 
matrix and neurons also play critical roles in influencing the behaviour of islet cells [11]. 
Beta cells are the dominant cell type of the human islet, accounting for 50% to 70% of islet 
cells [12]. Their main function, namely regulated insulin secretion, involves the integration 
of several stimuli which activate secretion when challenged and others that switch it off 
when the stimuli are no longer present. Whilst there is general agreement that the entry of 
glucose into the beta cell via specialised glucose transporters leads to a cascade of events 
including glucose phosphorylation by glucokinase and the closure of potassium-ion 
channels leading to membrane depolarisation and insulin secretion [13], the process is 
more complex. Following glucose entry into beta cells, insulin is secreted in two distinct 
phases and in an oscillatory, rather than a linear, pattern [14]. Further complexity can 
be found in the presence of secondary pathways of insulin secretion independent of ion 
channels [11], interactions between beta cells which influence behaviour [15] and the effect 
of gut-derived hormones, known as incretins, on beta-cell function [16]. The major steps in 
glucose-stimulated insulin secretion have been summarised in Figure 1. 
However our understanding of beta-cell physiology is incomplete, with lack of understanding 
of the roles of a broad system of G-protein coupled receptors on the beta-cell surface [17], 
the effect of other nutrients such as amino acids and fatty acids on beta-cell function [18] 
and the role of vitamin D activating enzymes and receptors within the beta cell [19]. In 
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seeking answers to these and many other questions, researchers in this field face a number 
of challenges. Significant inter-species differences in islet architecture [20] and responses 
to hyperglycaemia [21] pose a challenge that has made direct extrapolation of disease-
related pathophysiology from rodents to humans tricky. Furthermore, the study of human 
pancreatic specimens, whilst insightful, does not always reflect in vivo beta-cell behaviour.
Figure 1. Steps involved in glucose-stimulated insulin secretion by the pancreatic beta cell. 
Following entry of glucose via GLUT transporters, phosphorylation by glucokinase occurs 
and pyruvate is formed via the process of glycolysis. This leads to increased activity of the 
TCA cycle within the mitochondria by which adenosine diphosphate (ADP) is converted to 
adenosine triphosphate (ATP). This causes closure of ATP-sensitive potassium channels, a 
wave of membrane depolarisation and the subsequent activation of voltage gated calcium 
channels. The entry of calcium into the cell is followed by vesicle docking and insulin 
granules are released into the circulation. Other factors play a role such as glucagon-like 
peptide 1 which has unique receptors in the beta-cell membrane. 
There is no doubt that beta cells play an important role in the pathogenesis of type 2 diabetes 
but the complex nature of these cells and the difficulties encountered in ‘unlocking’ some 
of these complexities have inevitably led to some controversy in our understanding of the 
precise nature of this role. 
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Insulin resistance or defective beta cells?
A controversial issue for many years has been whether insulin resistance or impaired beta-
cell function is the primary cause of type 2 diabetes. This controversy seems to have resulted 
from the complex interaction between both defects present early in the disease and the 
relative ease in measuring in vivo insulin resistance as compared to beta-cell function [22].
A 1992 study examining non-diabetic subjects at high risk of developing type 2 diabetes 
(ie women with prior gestational diabetes, high risk ethnic groups, people whose parents 
were both affected by type 2 diabetes) reported that insulin resistance was the predominant 
feature [23]. This was based on a glucose tolerance test which demonstrated supra-
physiological insulin levels required to maintain normal glucose at two hours following 
a 75 gm oral glucose load. However, by only obtaining two-hour measurements, the high 
insulin levels were misinterpreted as representing normal beta-cell function compensating 
for a state of insulin resistance. As discussed above, insulin secretion is normally biphasic 
and the first phase of insulin secretion, maximal at 30 minutes following a meal, appears 
to be the first casualty of the beta cell in type 2 diabetes [12] Therefore, if values were 
measured at 30 minutes following the glucose load, different levels may have been found 
which would match the early rise in glucose, then followed by compensatory insulin hyper-
secretion at two hours.
A prospective study of 200 non-diabetic Pima Indians, which is a group with a very high 
risk of type 2 diabetes, also reported that insulin resistance was the earliest feature in 
the 38 patients who went on to develop diabetes [24]. Lifestyle factors, such as obesity, 
sedentary lifestyle and high-fat diets correlated closely with this state of insulin resistance 
which was detected by the gold-standard technique, the hyperinsulinaemic-euglycaemic 
clamp. However, as the disease developed, the degree of insulin resistance did not change 
significantly but rather, a dynamic pattern of beta-cell activity emerged with early 
hyperinsulinaemia to maintain normoglycaemia being followed by a significant drop in 
insulin levels resulting in hyperglycaemia. It was therefore proposed that beta-cell failure 
was the final determinant in the development of hyperglycaemia in these patients. 
For some time, ‘beta-cell exhaustion’ was the sole explanation for the failure in insulin 
secretion [20]. This is the concept that after a prolonged period of producing high 
amounts of insulin in order to overcome an insulin resistant state, otherwise normal 
beta cells eventually ‘burn out’ and permanently fail. Proponents of this hypothesis 
also describe distinct stages in the evolution of beta cells from a state of compensation 
to severe decompensation [25]. But the exhaustion concept has some limitations. Most 
patients with conditions characterised by insulin resistance – such as pregnancy, morbid 
obesity, Cushing’s disease and acromegally – do not develop diabetes. Furthermore, studies 
in humans and rhesus monkeys suggest that the early hyperinsulinaemia may occur 
independently of insulin resistance and rather reflect ‘beta-cell hyper-responsiveness’ 
[26]. In addition, patients with mutations in the insulin receptor, who have severe insulin 
resistance from birth do not develop diabetes until their beta cells fail, usually in their teens 
or 20s [27]. Therefore, intrinsic defects in susceptible beta cells appear to be important 
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both early in the development of diabetes and later when the cells undergo critical failure 
in their compensatory capacity. 
Another five-year prospective study involving non-diabetic Pima Indians confirmed dual 
pathology involving both the beta cell and peripheral insulin sensitivity in the development 
of diabetes [28]. Amongst 48 non-diabetic subjects who were roughly equal for parameters 
of obesity and insulin resistance, the 17 who progressed to diabetes failed to increase their 
insulin secretion in response to progression of insulin resistance. Furthermore, they showed 
signs of defective beta-cell function even before the onset of impaired glucose tolerance. 
The 31 subjects who did not progress to diabetes demonstrated appropriate increases in 
insulin secretion as they gained weight and became more insulin resistant. Therefore, it 
was beta-cell function that determined the progression from insulin resistance to frank 
diabetes in this high-risk group. 
A useful way to understand the interaction between insulin sensitivity and beta-cell 
function can be found in the disposition index [29]. In normal subjects, beta-cell function 
varies according to the degree of insulin sensitivity so that when non-diabetic individuals 
enter a phase of greater insulin resistance, such as in puberty, pregnancy or aging, beta cells 
‘rise to the occasion’ and produce greater insulin as required. The relationship follows a 
hyperbolic pattern as seen in Figure 2, indicating a continuum of beta-cell responsiveness 
to variations in insulin sensitivity. The dotted, downward line in this figure represents the 
progression to diabetes as was displayed in the previous study [25] – while still glucose 
tolerant, susceptible individuals began to ‘fall below the curve’ with the inability of beta cells 
to respond appropriately to the degree of insulin resistance. The downward, rather than 
horizontal, trajectory of this dotted line indicates that deterioration in beta-cell function 
was of greater importance than the reduction in insulin sensitivity in the development of 
hyperglycaemia [20]. Therefore, in essence, type 2 diabetes may be considered a failure of 
beta-cell compensation.
Beta-cell failure and insulin resistance however need not be considered as separate entities. 
Pathways are emerging by which these otherwise disparate conditions may be linked. Striking 
examples exist in the insulin signalling pathway. For example, insulin receptor substrate-2 
(IRS-2) promotes both cell growth, insulin secretion and plays a well-recognised role in 
insulin sensitivity [30]. Mice with IRS-2 mutations in their beta-cells develop diabetes. In 
addition, people with Akt2 mutations develop diabetes due to the combination of severe 
insulin resistance and impaired beta-cell dysfunction [31]. Insulin receptor mutations also 
associate with diabetes, both in people, and in mice. The transcription factor NF-kappaB 
plays an important role in both insulin resistance [32] and beta-cell behaviour [33]. 
Furthermore, complex processes which alter the behaviour of the mitochondria, the cell’s 
own ‘energy plant’, are similar in insulin-resistant tissues and defective beta cells. Therefore, 
insulin resistance and beta-cell dysfunction may be aetiologically related and rather than 
predominating over the other, appear to conspire together in the development of diabetes.
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Reduced beta-cell mass or function? 
Currently, there is a debate concerning the relative roles of decreased beta-cell mass 
compared with decreased beta-cell function in diabetes pathogenesis [34]. 
Proponents of the reduced beta-cell mass argument refer to postmortem studies which 
demonstrate up to 40% reduction in the number of beta cells in subjects with prediabetes 
versus weight-matched non-diabetic individuals [35]. In addition, mutations of genes 
known to control beta-cell mass such as the pancreatic and duodenal homeobox 1 (Pdx-1) 
result in monogenic forms of diabetes, such as Maturity Onset Diabetes of the Young [36].
Figure 2. The ‘disposition index’ is a useful way to consider the relationship between insulin 
secretion and insulin sensitivity in both physiologic (ie curved line) and pathologic states (ie 
dotted line). This is based on data from a number of studies and has been adapted from 
Kahn et al. [26]. Individuals who develop type 2 diabetes head in a downward trajectory 
below the curve indicating that deterioration in beta-cell function (and thus less insulin 
secretion) is the main factor in the development of hyperglycaemia.
However, there are some limitations to this argument. Firstly, not all autopsy studies in 
diabetic subjects demonstrate relative reductions in beta-cell mass [37]. Secondly, beta-cell 
mass is highly variable even in normal individuals and may undergo substantial changes 
throughout a person’s life [7]. Thirdly, it is difficult to see how a reduction of less than 
50% of otherwise healthy beta cells could cause diabetes in the light of a recent in vivo 
islet donation from 50% of a healthy human pancreas which resulted in diabetes cure in 
the recipient and the absence of diabetes in the donor [38]. Furthermore, normal rats 
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that underwent a 60% pancreatectomy remained normoglycaemic due to partial beta-cell 
regeneration and hyperfunction of remaining beta cells [39]. However, when these rats 
were challenged by the addition of 10% sugar to their water supply, impairment of the 
residual beta-cell mass and subsequent hyperglycaemia ensued. Therefore, in isolation, 
reduced beta-cell mass was insufficient to cause diabetes but rather required the presence 
of environmental factors to unmask the effect.
There are well-described functional defects in the beta cells of subjects with diabetes. As 
mentioned earlier, the loss of first phase insulin secretion is a particularly early defect [12]. 
Another is the loss of oscillations in insulin secretion, the importance of which relates 
to the regulation of hepatic glucose production under physiological conditions [40]. This 
may occur early in the disease, being found in non-diabetic relatives of people with type 
2 diabetes [41]. Thirdly, inefficient conversion of the precursor peptide, pro-insulin, into 
insulin results in a four to fivefold increase in pro-insulin levels in the beta cells of patients 
with type 2 diabetes [42]. 
Defects within the incretin system may also result in early beta-cell dysfunction [14]. The 
incretins are a pair of gut hormones, namely glucagon-like peptide 1 and glucose-dependent 
insulinotropic polypeptide, which are released into the bloodstream after meal ingestion 
and stimulate insulin secretion in a glucose-dependent manner. The incretins increase the 
expression of genes important for insulin secretion, such as the GLUT2 and glucokinase 
genes, and beta-cell proliferation, such as PDX-1. Subjects with type 2 diabetes may display 
down-regulation of incretin receptors on the surface of beta cells [43], impaired incretin-
induced insulin secretion [44] and increased degradation of incretin hormones [45]. Non-
diabetic relatives of those with diabetes [46] and people with impaired glucose tolerance 
[47] may also display defects in the incretin system. 
A whole range of gene expression defects are also associated with beta-cell dysfunction. 
My research group have previously demonstrated that proteins vital to beta-cell function 
and insulin secretion, known as the transcription factors HIF-1a [48] and ARNT [49], have 
significantly less expression in the pancreatic islets of diabetic versus non-diabetic subjects. 
Knockout mice lacking the genes for these proteins in insulin expressing cells develop 
glucose intolerance and impaired insulin secretion [44, 45]. In fact, the advent of genome-
wide association studies (GWAS) in 2007 has led to an explosion of data on the possible 
genetic background of type 2 diabetes [20]. GWAS uses thousands of small nucleotide 
sequences throughout the genome to search for patterns linked to disease, using the human 
genome sequencing project as reference. The transcription factor 7-like 2 (TCF7L2) is to 
be most strongly linked to type 2 diabetes with important effects on beta-cell proliferation 
and function [50], incretin-related insulin secretion [39] and insulin secretion [51]. 
Polymorphisms in TCF7L2 are thought to account for ~20% of the population attributable 
risk of diabetes [52]. The important point here is that the genetic determinants of beta-cell 
function and mass appear closely linked.
Some investigators now refer to ‘reduced functional beta-cell mass’ rather than debating 
the predominance of reduced mass or defective function in diabetes causation [53]. The 
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‘plasticity’ of the functional beta-cell mass, that is, the concept that beta cells can undergo 
adaptive changes in both mass and function when challenged by insulin resistance has also 
received some attention. 
Mechanisms of beta-cell failure
If defects in the functional beta-cell mass play such a critical role in diabetes pathogenesis, 
what are some of the mechanisms responsible for these defects? These have been 
summarised in Figure 3.
Figure 3. Proposed mechanisms of pancreatic beta (beta) cell dysfunction and death in type 
2 diabetes. This flow-chart depicts the complex and multifactorial nature of cell dysfunction 
in this condition. For a description of the concepts and terms see the text.
Pancreatic islet inflammation
There is mounting evidence that chronic low-grade inflammation of the pancreatic islet 
can cause insulin secretory dysfunction and beta-cell apoptosis [54]. Most striking is the 
macrophage infiltration seen in the islets of mice and humans with type 2 diabetes prior 
to the onset of beta-cell death [55]. It is also known that islets and ductal cells respond to 
metabolic stress, such as hyperglycaemia [56] and exposure to fatty acids, by expressing 
cytokines particularly IL-1beta. While this may initially be protective, chronic expression 
of this cytokine may result in the production of reactive oxygen species, inflammation and 
eventual beta-cell death [49]. Furthermore, the use of anti-inflammatory therapies, such as 
an IL-1 receptor antagonists [57] or non-steroidal anti-inflammatory drugs [58] results in 
small improvements in beta-cell function independent of an effect on insulin resistance. 
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Inflammatory markers, such as the serum leukocyte count and c-reactive protein, are also 
elevated in patients with type 2 diabetes and in those at risk of diabetes [59].
There is emerging evidence linking obesity and beta-cell failure via an inflammatory 
pathway. Leptin, a hormone secreted by fat cells to control appetite, is often found in high 
levels in type 2 diabetes [60] and at such levels, has negative effects on insulin secretion 
[61] and may induce beta-cell apoptosis [62]. Conversely, adiponectin which has anti-
inflammatory and insulin sensitising effects, appears to be down-regulated in diabetes 
[63]. In addition, fat-derived cytokines, fatty acids and lipoproteins may all have adverse 
effects on beta-cell function, suggesting a common inflammatory link between the various 
components of the metabolic syndrome. 
Figure 4. Islet amyloid deposition in a human with type 2 diabetes In the islet of this 
patient with diabetes, amyloid infiltration is seen as bright plaques in this grey scale image, 
thioflavin S stain.
Islet amyloid
Although islet amyloidosis has long been associated with beta-cell loss in type 2 diabetes 
[64], its precise role is uncertain. At postmortem, more than 90% of type 2 diabetic subjects 
have amyloid deposits in at least one islet compared to 12% of age-matched non-diabetic 
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patients [65]. However, the number of islets affected is highly variable [66] and there is no 
relationship between duration of diabetes and the presence or severity of islet amyloid [67].
Islet amyloid fibrils are composed of amylin, a normally occurring peptide of the beta cell 
co-stored with insulin, which has folded abnormally and is initially deposited around islet 
capillaries but later within the islet space [30]. The increased production of pro-amylin 
accompanies the higher pro-insulin levels characteristic of type 2 diabetes and may be the 
first step to developing islet amyloid [68].
Although synthetic amyloid fibrils induce early beta-cell death in vitro [69], it is unclear 
whether amyloidosis is the direct cause of beta-cell failure in vivo or rather, the end-result 
of several distinct processes including inflammation, oxidative stress and mitochondrial 
damage. It is also currently debated whether the amyloid plaques per se are cytotoxic or 
rather small intracellular molecules that are precursors in the development of such plaques [70].
Endoplasmic reticulum stress
The endoplasmic reticulum (ER), a highly developed organelle that resides within the cell, is 
responsible for protein handling and packaging. Due to the high secretory demand placed 
on beta cells in type 2 diabetes, the endoplasmic reticulum may become overwhelmed by 
the production of high level of proteins [71]. A process called ER stress ensues whereby 
intracellular signals intending to protect the beta cells from the effects of inflammation [72] 
may eventually lead to the impairment of beta-cell function, the morphological appearance 
of ER swelling as proteins accumulate and subsequent beta-cell death. 
ER stress may be mediated via genetic and environmental factors. Mice with mutations 
in proinsulin develop diabetes with morphological evidence of ER stress [20]. Exposure 
of islets to high glucose levels, cytokines and fatty acids may also lead to signs of ER stress 
[73]. 
Glucose toxicity
Glucose is the key physiological regulator of insulin secretion. Chronic hyperglycaemia is 
associated with impaired insulin secretion [74] and restoring normoglycaemia in subjects 
with diabetes has a clearly positive effect on beta-cell function [75].
There are several ways by which the exposure of beta cells to high glucose levels has 
toxic effects (glucotoxicity). The term ‘beta-cell dedifferentiation’ refers to an altered 
pattern of gene expression that results in substantial functional defects related to chronic 
hyperglycaemia [76]. Changes in beta-cell signalling and architecture are also possible 
effects of high glucose exposure [77]. The overproduction of reactive oxygen species, 
known as oxidative stress, is related to mitochondrial metabolism of high glucose levels 
and may result in beta-cell dysfunction or death [20]. 
Support for the oxidative stress hypothesis has come from a number of animal and human 
studies. The beta-cell over-expression of glutathione peroxidase, the enzyme that protects 
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cells from oxidative damage, improved beta-cell mass and function in diabetic mice [78]. 
Higher concentrations of oxidative stress markers were found in islets from human subjects 
with type 2 diabetes and marked improvement in insulin secretion followed 24 hours of 
exposure to glutathione [79].
The failure of the beta cell’s adaptive response to high glucose levels may precede dysfunction. 
The Fas-FLIP pathway involves a series of factors which are upregulated in response to 
high glucose levels and which result in greater beta-cell differentiation, proliferation and 
function [80]. However, in chronic hyperglycaemia, this adaptive pathway may eventually 
fail resulting in deterioration in beta-cell function and reduced survival [49]. 
Lipotoxicity 
Whilst effective insulin secretion requires the presence of fatty acids [81], long-term 
exposure to excessive levels of this nutrient may also result in beta-cell toxicity [30]. 
The precise mechanism of so-called lipotoxicity is unclear but it may be due to genetic 
alterations in the expression of insulin and enzymes controlling insulin secretion [82], 
metabolic disturbances and ultimately, beta-cell death. 
Studies in the Zucker diabetic fatty rat, considered a good model for obesity-related type 2 
diabetes, have shown that the development of hyperlipidaemia parallels inadequate insulin 
secretion and the onset of diabetes [83]. However the lipid levels in this animal model are 
often extreme, so whether this reflects the human condition is debatable. Furthermore, 
fewer than 12% of obese hyperlipidaemic human subjects become diabetic [84], suggesting 
that lipotoxicity may be just one component in the development of beta-cell failure in type 
2 diabetes. 
Beta-cell exhaustion 
It is speculated that after a prolonged period of insulin hypersecretion, depletion of readily 
available insulin granules may occur, thereby reducing the insulin secretory response 
[20]. Although we previously discussed the limitations of beta-cell exhaustion as the sole 
pathogenic mechanism, it may play a role in the wider, multifactorial setting of diabetes 
pathogenesis. 
The strongest support for the exhaustion concept comes from studies examining the benefits 
of ‘beta-cell rest’ strategies. When inhibitors of insulin secretion, such as diazoxide or 
somatostatin, are given to animals or humans with diabetes, paradoxical increases in beta-
cell function are observed following a period of ‘rest’ [85, 86]. Furthermore, human subjects 
with poorly controlled diabetes demonstrate a dramatic improvement in beta-cell function 
following a brief period of intensive glycaemic control [67]. A multicentre, randomised 
study of over 350 newly diagnosed patients confirmed that early intensive insulin therapy 
may facilitate recovery and maintenance of beta-cell function and protracted glycaemic 
remission better than oral hypoglycaemic agents for at least one year after diagnosis [87].
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This leads to the discussion of the therapeutic implications of beta-cell failure and the 
possibility of reversing this complex process. Although a highly controversial and evolving 
area of research, the use of certain sulfonylureas such as glibenclamide has been linked 
to beta-cell death [88], while there is mounting evidence that incretin-based therapy and 
insulin replacement increase beta-cell mass in mice and have a positive effect on function 
[89]. However, a discussion on the nuances of beta-cell preservation in type 2 diabetes 
is beyond the scope of this chapter. For such a discussion, we refer the reader to a recent 
review on this topic [81].
Conclusion
Pancreatic beta-cell dysfunction plays a vital and complex role in the pathogenesis of type 
2 diabetes. Ultimately, it is the failure of beta cells to respond to the insulin requirements 
posed by the prevailing level of insulin resistance that leads to the development of type 2 
diabetes. We have discussed the evidence in support of various genetic and environmental 
factors that conspire together in this state of beta-cell susceptibility and ‘decompensation’. 
The precise role of each and the search for a hypothesis which may unify these disparate 
concepts into a single paradigm is highly contentious and under active investigation. 
However, there is no doubt that beta-cell demise occurs in stages with early defects in 
beta-cell dysfunction, such as loss of first phase insulin secretion resulting in post-prandial 
hyperglycaemia following which progressive rises in glucose levels, fatty acids and insulin 
resistance place further stress on the beta cell, leading to eventual decline in its secretory 
capacity. Subtle components of the beta-cell stress mechanism, initially adaptive, such as 
changes to the endoplasmic reticulum and mitochondrium also eventually exacerbate 
the situation. Recent evidence suggests that early intervention to improve glycaemic 
control may improve beta-cell function and for at least a limited time period, may retard 
progression to beta-cell failure. Further research into the complex mechanisms of beta-cell 
failure may therefore offer hope in our collective fight against the global epidemic of type 
2 diabetes.
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